Synaptogenix Inc (SNPX)

[runncoach]

I think if more than 80% of patients show an average improvement over 6 months similar to what we've seen in the first 2 trials in this moderate population we won't have to wait until P3 to reap the rewards. I think that's the biggest knock so far, that is the trial length needs to match up with memantine to really draw the comparison to current SOC. It certainly can't be argued that patients on the drug haven't improved objective test scoring so far.